Rudolf Tauber

Prof. Dr. Rudolf Tauber

Institute for Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité-Universitätsmedizin Berlin, D-13353 Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2014 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
AAAndreas Adler
Andreas Adler
SGSebastian Geiger
Sebastian Geiger
AKAnne Keil
Anne Keil
HBHarald Bias
Harald Bias
PSPhilipp Schatz
Philipp Schatz
BWBertram Wiedenmann
Bertram Wiedenmann
Despite strong recommendations for colorectal cancer (CRC) screening, participation rates are low. Understanding factors that affect screening choices is essential to developing future screening strategies. Therefore, this study assessed patient willingness to use non-invasive stool or blood based screening tests after refusing colonoscopy.

16 November 2020 in Biomarkers
Verified
Journal Article
Closed access
KKKai Kappert
Kai Kappert
AJAmir Jahić
Amir Jahić
Rudolf TauberRudolf Tauber
Rudolf Tauber
BACKGROUND: The 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has an impact on all aspects of patient care. Serum ferritin generally represents a biomarker of choice when iron deficiency is suspected. However, ferritin is also an acute-phase-protein exhibiting elevated serum concentrations in various inflammatory diseases. Here we focus on the role of serum ferritin for diagnostic and clinical management of patients with COVID-19 in comparison with other infectious and non-infectious diseases. METHODS: We examined scientific articles listed in PubMed reporting on ferritin in various infectious and non-infectious diseases. We then compared these results with nine current COVID-19 ferritin reports published in 2020. RESULTS: Several non-infectious as well as non-COVID-19 infectious diseases are characterized by a partly dramatic elevation of serum ferritin levels. All COVID-19 studies published between February and May 2020, which documented laboratory serum ferritin, indicate ferritin as a diagnostic biomarker of COVID-19 severity in hospitalized patients. CONCLUSIONS: Serum ferritin may be considered both a prognostic and stratifying biomarker that can also contribute to therapeutic decision-making concerning patients with COVID-19. It should be emphasized, however, that most scientific reports refer to cohorts in the Asian region. Further validation in other cohorts is urgently required.

1 September 2019 in Radiology
Verified
Journal Article
Closed access
ESEva Schönenberger
Eva Schönenberger
PMPeter Martus
Peter Martus
MBMaria Bosserdt
Maria Bosserdt
EZElke Zimmermann
Elke Zimmermann
Rudolf TauberRudolf Tauber
Rudolf Tauber
MDMarc Dewey
Marc Dewey
In patients suspected of having coronary artery disease, intravenous contrast agent administration for coronary CT angiography had a lower rate of acute kidney injury compared with intra-arterial c... Background In the absence of randomized studies, it has been controversial whether the likelihood of acute kidney injury (AKI) differs between intravenous and intra-arterial contrast agent administ...

10 June 2013 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
MDMax J Dörfel
Max J Dörfel
JWJulie K Westphal
Julie K Westphal
CBChristian Bellmann
Christian Bellmann
Susanne M KrugSusanne M Krug
Susanne M Krug
JCJimmi Cording
Jimmi Cording
Otmar HuberOtmar Huber
Otmar Huber
Background: Casein kinase 2 (CK2) is a ubiquitously expressed Ser/Thr kinase with multiple functions in the regulation of cell proliferation and transformation. In targeting adherens and tight junctions (TJs), CK2 modulates the strength and dynamics of epithelial cell-cell contacts. Occludin previously was identified as a substrate of CK2, however the functional consequences of CK2-dependent occludin phosphorylation on TJ function were unknown. Results: Here, we present evidence that phosphorylation of a Thr400-XXX-Thr404-XXX-Ser408 motif in the C-terminal cytoplasmic tail of human occludin regulates assembly/disassembly and barrier properties of TJs. In contrast to wildtype and T400A/T404A/S408A-mutated occludin, a phospho-mimetic Occ-T400E/T404E/S408E construct was impaired in binding to ZO-2. Interestingly, pre-phosphorylation of a GST-Occ C-terminal domain fusion protein attenuated binding to ZO-2, whereas, binding to ZO-1 was not affected. Moreover, Occ-T400E/T404E/S408E showed delayed reassembly into TJs in Ca2+-switch experiments. Stable expression of Occ-T400E/T404E/S408E in MDCK C11 cells augments barrier properties in enhancing paracellular resistance in two-path impedance spectroscopy, whereas expression of wildtype and Occ-T400A/T404A/S408A did not affect transepithelial resistance. Conclusions: These results suggest an important role of CK2 in epithelial tight junction regulation. The occludin sequence motif at amino acids 400–408 apparently represents a hotspot for Ser/Thr-kinase phosphorylation and depending on the residue(s) which are phosphorylated it differentially modulates the functional properties of the TJ.

30 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EBElena Ioana Braicu
Elena Ioana Braicu
CKCatherine Linn Krause
Catherine Linn Krause
UTUwe Torsten
Uwe Torsten
HMHerbert Mecke
Herbert Mecke
RRRolf Richter
Rolf Richter
JSJalid Sehouli
Jalid Sehouli
Background: To evaluate the diagnostic value of adding human epididymis protein 4 (HE4), cancer antigen 125 (CA125) and risk of malignancy algorithm (ROMA) to ultrasound for detecting ovarian cancer in patients with a pelvic mass. Methods: This was a prospective, observational, multicenter study. Patients aged > 18 years who were scheduled to undergo surgery for a suspicious pelvic mass had CA125 and HE4 levels measured prior to surgery, in addition to a routine transvaginal ultrasound scan. The diagnostic performance of CA125, HE4 and ROMA for distinguishing between benign and malignant adnexal masses was assessed using receiver operating characteristic (ROC) analysis and the corresponding area under the curve (AUC). Results: Of 965 evaluable patients, 804 were diagnosed with benign tumors and 161 were diagnosed with ovarian cancer. In late-stage ovarian cancer, CA125, HE4 and ROMA all had an excellent diagnostic performance (AUC > 0.92), whereas in stage I and II, diagnostic performance of all three biomarkers was less adequate (AUC < 0.77). In the differential diagnosis of ovarian cancer and endometriosis, ROMA and HE4 performed better than CA125 with 99 and 98.1% versus 75.0% sensitivity, respectively, at 75.4% specificity. Conclusions: ROMA and HE4 could be valuable biomarkers to help with the diagnosis of ovarian cancer in premenopausal patients in order to differentiate from endometriosis, whereas CA125 may be more adequate for postmenopausal patients.

7 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
WBWolfgang Bauer
Wolfgang Bauer
Marcus WeberMarcus Weber
Marcus Weber
EDEva Diehl-Wiesenecker
Eva Diehl-Wiesenecker
NGNoa Galtung
Noa Galtung
MPMonika Prpić
Monika Prpić
KKKai Kappert
Kai Kappert
Background: We evaluated how plasma proteomic signatures in patients with suspected COVID-19 can unravel the pathophysiology, and determine kinetics and clinical outcome of the infection. Methods: Plasma samples from patients presenting to the emergency department (ED) with symptoms of COVID-19 were stratified into: (1) patients with suspected COVID-19 that was not confirmed (n = 44); (2) non-hospitalized patients with confirmed COVID-19 (n = 44); (3) hospitalized patients with confirmed COVID-19 (n = 53) with variable outcome; and (4) patients presenting to the ED with minor diseases unrelated to SARS-CoV-2 infection (n = 20). Besides standard of care diagnostics, 177 circulating proteins related to inflammation and cardiovascular disease were analyzed using proximity extension assay (PEA, Olink) technology. Results: Comparative proteome analysis revealed 14 distinct proteins as highly associated with SARS-CoV-2 infection and 12 proteins with subsequent hospitalization (p < 0.001). ADM, IL-6, MCP-3, TRAIL-R2, and PD-L1 were each predictive for death (AUROC curve 0.80–0.87). The consistent increase of these markers, from hospital admission to intensive care and fatality, supported the concept that these proteins are of major clinical relevance. Conclusions: We identified distinct plasma proteins linked to the presence and course of COVID-19. These plasma proteomic findings may translate to a protein fingerprint, helping to assist clinical management decisions.